Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 15,720 shares at $87.26 ($1.4M) on 2024-12-18, disclosed to the SEC on 2024-12-19.
Scheduled sale ($1.4M) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $87.26 | 1,190 | $104K | 7.4% |
| 2 | $87.26 | 1,190 | $104K | 7.4% |
| 3 | $88.70 | 3,373 | $299K | 21.4% |
| 4 | $88.70 | 3,373 | $299K | 21.4% |
| 5 | $89.31 | 3,157 | $282K | 20.2% |
| 6 | $89.31 | 3,157 |
| $282K |
| 20.2% |
| 7 | $90.24 | 280 | $25K | 1.8% |
| Total | $88.75 avg | 15,720 | $1.4M | 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |